Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 4Q Financial Reports: Schering-Plough | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

4Q Financial Reports: Schering-Plough

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schering-Plough

4Q Revenues: $2.3 billion (+6%)

4Q Earnings: $126 million (loss of $834 million 4Q2004)

FY Revenues: $9.5 billion (+15%)

FY Earnings: $269 million (loss of $947 million FY2004)

Comments: Sales increase for 4Q was driven by the growth of prescription pharmaceuticals, led by Peg-Intron, Rebetol, Nasonex and Remicade. Peg-Intron sales were $214 million, up 55%. Rebetol sales were $94 million, up 93%. Nasonex sales were $185 million, up 27%. Remicade sales were $251 million, up 19%. Pharma revenues do not include sales of the cholesterol products marketed in partnership with Merck. Global cholesterol joint venture sales, which include Vytorin and Zetia, totaled approximately $755 million for the quarter. R&D spending was $474 million for the quarter, up 17%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters